While Compugen's strategic focus on Fc reduced anti-TIGIT programs and partnerships with AstraZeneca show promise, the company faces financial challenges including a significant revenue decline and net loss. Additionally, extended timelines for clinical trials could impact progress. However, there is potential for substantial milestones and royalties from partnerships, and promising clinical data for ovarian cancer treatments.

Company Guidance

During Compugen's third quarter 2025 results conference call, the company provided guidance on various key metrics and strategic initiatives. Compugen emphasized its commitment to advancing its differentiated Fc reduced anti-TIGIT programs, highlighting the potential advantages over Fc active anti-TIGIT antibodies in terms of safety and efficacy. The company anticipates readouts from its TIGIT programs in 2026, with the potential for significant commercial opportunities, particularly with their partner AstraZeneca's rilfrogostomy, which has an estimated peak year revenue target of over $5 billion. Additionally, Compugen discussed its financial outlook, with a cash runway expected to fund operations into 2027. The company reported a cash balance of approximately $86 million as of September 30, 2025, and noted revenues of $1.9 million for 2025 compared to $17.1 million in 2024. R&D expenses for 2025 were approximately $5.8 million, while G&A expenses were about $2.2 million. The net loss for the year was approximately $6.98 million, with a loss per share of $0.07. Compugen remains focused on advancing its pipeline, including ongoing trials and partnerships with AstraZeneca and Gilead, which provide potential for over $1 billion in milestone payments and royalties.

Strong Position in Fc Reduced Anti-TIGIT Programs

Compugen emphasizes its strategic focus on Fc reduced anti-TIGIT programs, which are believed to have advantages over Fc active anti-TIGIT antibodies. The company highlights the potential improved immune activation and safety profile of COM902, an Fc reduced anti-TIGIT monoclonal antibody, with Phase III data from Arcus Gilead expected in 2026 as a potential catalyst.

Substantial Potential for AstraZeneca Partnership

The partnership with AstraZeneca for RILVA, an Fc reduced anti-PD-one TIGIT bispecific, is projected to have a potential commercial opportunity with a non-risk adjusted peak year revenue target of more than $5 billion. Compugen is eligible for regulatory and commercial milestones and mid-single digit tiered royalties.

Promising COM701 Data for Ovarian Cancer

Phase I trials of COM701 demonstrated clinical benefits for heavily pretreated platinum-resistant ovarian cancer patients, particularly those without liver metastasis. The ongoing MYA ovarian platform trial is addressing an unmet need for maintenance therapy in platinum-sensitive ovarian cancer.

Compugen (CGEN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CGEN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 19, 2026	2025 (Q4)	-0.07 / -	-0.07	―	―	―
Nov 10, 2025	2025 (Q3)	-0.08 / -0.07	0.01	-800.00% (-0.08)	―
Aug 06, 2025	2025 (Q2)	-0.06 / -0.08	-0.02	-300.00% (-0.06)	―
May 19, 2025	2025 (Q1)	-0.06 / -0.08	-0.08	0.00% (0.00)	―
Mar 04, 2025	2024 (Q4)	0.03 / -0.07	0.11	-163.64% (-0.18)	―
Nov 12, 2024	2024 (Q3)	-0.10 / 0.01	-0.11	109.09% (+0.12)	―
Aug 06, 2024	2024 (Q2)	-0.09 / -0.02	-0.11	81.82% (+0.09)	―
May 20, 2024	2024 (Q1)	-0.11 / -0.08	-0.11	27.27% (+0.03)	―
Mar 05, 2024	2023 (Q4)	0.10 / 0.11	-0.04	375.00% (+0.15)	―
Nov 07, 2023	2023 (Q3)	-0.10 / -0.11	-0.14	21.43% (+0.03)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CGEN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 10, 2025	$1.62	$1.67	+3.09%
Aug 06, 2025	$1.46	$1.46	0.00%
May 19, 2025	$1.39	$1.39	0.00%
Mar 04, 2025	$1.81	$1.68	-7.18%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Compugen (CGEN) report earnings?

Compugen (CGEN) is schdueled to report earning on Feb 19, 2026, Before Open (Confirmed).

What is Compugen (CGEN) earnings time?

Compugen (CGEN) earnings time is at Feb 19, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CGEN EPS forecast?

CGEN EPS forecast for the fiscal quarter 2025 (Q4) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing